abrdn Life Sciences Investors is a US-based company operating in industry. The company is headquartered in Philadelphia, Pennsylvania. abrdn Life Sciences Investors (the Fund) is a non-diversified closed-end management investment company. The Fund’s investment objective is to seek long-term capital appreciation by investing primarily in equity and related securities of the United States and foreign companies principally engaged in the development, production or distribution of products or services related to scientific advances in life sciences (including biotechnology, pharmaceuticals, diagnostics, managed healthcare and medical equipment, hospitals, healthcare information technology and services, devices, supplies and other healthcare-related sub-sectors), agriculture and environmental management (Life Sciences Companies). The Fund may invest up to 20% of its net assets in securities of foreign issuers, expected to be located primarily in Western Europe, Canada and Japan, and securities of United States issuers that are traded primarily in foreign markets. The Fund’s investment adviser is abrdn Inc.
HQL stock price ended at $19.03 on 木曜日, after rising 0.74%
On the latest trading day Jun 25, 2026, the stock price of HQL rose by 0.74%, climbing from $19.00 to $19.03. Throughout the session, the stock experienced a volatility of 2.01%, with prices fluctuating between a daily low of $18.95 and a high of $19.33. Alongside this price increase, trading volume also rose by 15.8K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 147.8K shares were traded, amounting to a market value of approximately $578.7M.